Introduction

As pharmaceutical supply chains become increasingly global and complex, CMC governance is evolving from a purely compliance-focused function into a strategic pillar of product excellence and supply reliability. For leaders overseeing external manufacturing networks, the challenge is no longer simply meeting regulatory requirements but ensuring consistent quality, technical rigor, and long-term product robustness across diverse partners and markets.

With extensive experience in CMC compliance and external supply oversight, Joana Gaspar brings a pragmatic and forward-looking perspective on how to align regulatory expectations, technical standards, and operational performance within outsourced models. As Associate Director, CMC Compliance Strategy, Integrations at Grünenthal, she ensures that external manufacturing partners operate with strong governance, scientific discipline, and a shared commitment to patient safety and supply continuity.

Ahead of her session, “From Compliance to Product Excellence: Strategic Evolution of CMC” at the European Pharma Outsourcing Summit, we spoke with Joana about the evolving role of CMC, strengthening collaboration with CMOs, embedding product excellence into governance frameworks, and preparing external supply networks for greater agility and digital maturity.

CMC is no longer only about meeting regulatory requirements—it has become a core strategic function enabling product robustness, lifecycle success, and reliable global supply.  

Could you begin with a brief introduction about yourself, and an overview of your responsibilities as Associate Director, CMC Compliance Strategy, Integrations  at Grünenthal? 

As Associate Director, CMC Compliance Strategy – Integrations at Grünenthal, I am responsible for CMC governance across outsourced manufacturing, external supply networks, and global technology transfer activities. I work closely with internal stakeholders and CMOs to ensure robust documentation, clear compliance standards, and inspection‑ready processes. I’ve supported major product integrations and post‑approval changes across multiple external partners, and I bring a pragmatic, partnership‑oriented approach to strengthening CMO collaboration and enabling efficient, compliant outsourcing outcomes. 

From your perspective, how is the role of CMC evolving from a compliance-driven function to a strategic enabler of product excellence in external supply? 

CMC is no longer only about meeting regulatory requirements, it has become a core strategic function enabling product robustness, lifecycle success, and reliable global supply. In external supply, CMC acts as the bridge between regulatory expectations, technical feasibility, and commercial needs. The strategic value lies in anticipating risks early, shaping decisions with data, and ensuring that CMOs operate with the same product understanding as internal manufacturing sites. 

How can insights from clinicians and real-world clinical use be more effectively integrated into early design and development decisions?

 A key challenge is ensuring that external manufacturing partners fully understand the scientific and regulatory rationale behind CMC expectations—not just the regulatory requirements. Variability in systems, culture, and technical knowledge can lead to inconsistent execution. Aligning on documentation standards, change management and timelines requires constant engagement. 

 Balancing strict compliance with a drive for improvement requires a mindset shift: compliance is the baseline, not the ceiling. 

How do you balance regulatory compliance with the need to drive continuous improvement and product robustness in outsourced supply chains?

Balancing strict compliance with a drive for improvement requires a mindset shift: compliance is the baseline, not the ceiling. I encourage partners to treat regulatory expectations as an opportunity to strengthen product understanding and process capability. By using structured risk assessments, data reviews, and lifecycle management principles, we can implement improvements without compromising compliance. The focus is always on patient safety, supply continuity, and long‑term robustness. 

When working with external partners, which CMC indicators best signal long-term product quality and reliability? 

 The most meaningful indicators include: process capability trends, stability program performance, change control quality, and the ability to execute CMC commitments on time. 

The most meaningful indicators include: process capability trends, stability program performance, change control quality, and the ability to execute CMC commitments on time. A partner’s responsiveness, transparency, and scientific rigor are also strong predictors. Consistent deviation management and clear root‑cause analysis show technical maturity. Together, these elements signal whether a partner can reliably maintain product quality throughout its lifecycle 

How do you embed a mindset of product excellence within CMC governance models for external supply?  

 We embed a mindset of product excellence by making science, quality, and patient impact central to every CMC governance discussion. This means using clear product‑focused metrics, encouraging open collaboration with our external partners, and maintaining strong technical oversight throughout the product lifecycle. When leaders consistently ask the right technical questions and focus on continuous improvement, excellence becomes part of how everyone works—not just a compliance requirement. 

What role do cross-functional collaboration and early CMC involvement play in strengthening external supply outcomes? 

Strong cross‑functional collaboration is essential, especially in an external supply model. Early CMC involvement ensures that technical assumptions, regulatory implications, and supply risks are identified before they become issues. It accelerates decision‑making, strengthens project planning, and ensures that changes are executed smoothly. Early collaboration also helps external partners understand expectations upfront, reducing late-stage surprises. 

Looking ahead, how do you see CMC functions further evolving to support innovation, agility, and excellence in external supply networks? 

Greater digital maturity, streamlined governance, and more integrated quality‑technical collaboration will enhance speed and consistency across partners. As data becomes more connected and processes more harmonized, CMC teams will be able to anticipate issues earlier, adapt faster, and guide innovation with clearer insight. This evolution will support not only agility and reliability but also a more proactive, partnership‑driven model of external supply excellence. 

 Which aspect of the European Pharma Outsourcing Summit are you most looking forward to? 

I’m looking forward to meaningful discussions with peers facing similar challenges in external supply, particularly around CMC governance, risk management, and partner collaboration. The Summit is a valuable opportunity to benchmark practices, explore new models for oversight, and exchange insights on how to evolve CMC into an even stronger strategic function supporting efficiency, compliance, and product excellence. 

Conclusion

Joana Gaspar’s insights reinforce a critical shift in mindset: CMC is no longer a back-end compliance safeguard, it is a strategic enabler of product quality, resilience, and long-term supply performance. In external manufacturing models, excellence depends on scientific alignment, strong governance, proactive risk management, and true partnership with CMOs.

As external supply networks grow more complex and interconnected, CMC leadership will play an increasingly central role in driving consistency, agility, and innovation without compromising compliance. Her session, “From Compliance to Product Excellence: Strategic Evolution of CMC” will provide practical guidance for organizations seeking to strengthen oversight, enhance collaboration, and build external supply models that are not only compliant but sustainably excellent.

Register now: eposummit.com